Riskpilot← Back to searchSign inGet full accessPromega Biotech AB
ABActiveOrg 5567177893Finnboda Varvsväg 16Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200610 employees
Revenue 2025
SEK 115,8M
+19% vs 2024
EBITDA margin
8.2%
-29% vs 2024
Equity ratio
33.6%
Financial strength
Net profit 2025
SEK 7M
-23% vs 2024
| Revenue | SEK 115,8M | +19% |
| EBITDA | SEK 9,5M | -29% |
| Net profit | SEK 7M | -23% |
| Total assets | SEK 49,6M | +35% |
| Equity | SEK 16,7M | +73% |
| Employees | 10 | — |
Legal name
Promega Biotech AB
Org number
5567177893
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 december 2006
Share capital
SEK 100 000
Employees
10 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt sälja och marknadsföra utrusning inom biotech- och läkemedelsindustrin, och därmed förenlig verksamhet.
Address
Finnboda Varvsväg 16
Phone
+46761044706
Email
patrick.vandevelde@promega.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 75 681 | 83 253 | 87 854 | 96 974 | 115 781 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 7 083 | 6 976 | 12 774 | 13 370 | 9 478 |
| Depreciation & amort. | −240 | −222 | −165 | −109 | −65 |
| EBIT | 6 843 | 6 754 | 12 609 | 13 261 | 9 413 |
| Net financials | — | — | 1 | 33 | −7 |
| Profit before tax | 5 810 | 5 439 | 10 255 | 11 714 | 8 957 |
| Tax | −1 259 | −1 151 | −2 188 | −2 530 | −1 912 |
| Net profit | 4 551 | 4 288 | 8 067 | 9 184 | 7 045 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 27 885 | 34 800 | 42 719 | 36 839 | 49 580 |
| Equity | 8 087 | 12 376 | 20 443 | 9 627 | 16 672 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 11 308 | 12 619 | 10 116 | 13 472 | 18 718 |
| Total debt | 11 308 | 12 619 | 10 116 | 13 472 | 18 718 |
EBITDA margin
8.2%
This company
15.8%
Market median
-48% vs market
20212025
Equity ratio
33.6%
This company
38.2%
Market median
+12% vs market
20212025
Return on equity
42.3%
This company
18.4%
Market median
+130% vs market
20212025
Net profit margin
6.1%
This company
8.1%
Market median
-25% vs market
20212025
Asset turnover
2.34×
This company
1.12×
Market median
+109% vs market
20212025
Debt / equity
1.97×
This company
0.62×
Market median
-218% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PS Chief Executive Officer | Chief Executive Officer | 2022 |
HP Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Promega Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patrick Simon Van de Velde | Chief Executive Officer | 0 companies |
| Hans Peter Ek | Chief Auditor | 0 companies |
| Hans-Joachim Müller | Board of Directors | 0 companies |
| William A Linton | Chairman | 0 companies |